The DOI matches its Crossref record; 542 of the 542 references it cites were found in a registry or an index.
The Glucagon-Like Peptides
Abstract
I. Introduction II. History of the Incretin Concept: Discovery of Gastric Inhibitory Polypeptide III. Discovery of GLP-1 IV. Structures of GLPs and Family of Glucagon-Related Peptides V. Tissue Distribution of the Expression of GLPs A. Pancreatic α-cells B. Intestinal L cells C. Central nervous system VI. Proglucagon Biosynthesis A. Organization/structure of the proglucagon gene B. Regulation of glucagon gene expression C. Posttranslational processing of proglucagon VII. Regulation of GLP Secretion A. Overview B. Intracellular signals C. Carbohydrates D. Fats E. Proteins F. Endocrine G. Neural H. GLP-2 VIII. Metabolism of GLPs A. GLP-1 B. GLP-2 IX. Physiological Actions of GLPs A. Overview B. Pancreatic islets C. Counterregulatory actions of GLP-1 and leptin on β-cells D. Stomach E. Lung F. Brain G. Liver, skeletal muscle, and fat H. Pituitary, hypothalamus, and thyroid I. Cardiovascular system J. GLP-2 X. GLP Receptors A. Structure B. Signaling C. Distribution D. Regulation E. GLP-2 XI. Pathophysiology o...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt
Potten, C. S., & Loeffler, M. (1990) · Development · doi:10.1242/dev.110.4.1001 · Cited by 1,791
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
The mechanism of pancreatic secretion
Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,269
A G Protein-Linked Receptor for Parathyroid Hormone and Parathyroid Hormone-Related Peptide
Jüppner, H., Abou-Samra, A.-B., Freeman, M., Kong, X. F., Schipani, E., Richards, J., Kolakowski, L. F., Hock, J., Potts, J. T., Kronenberg, H. M., et al. (1991) · Science · doi:10.1126/science.1658941 · Cited by 1,249
Research works printed but not linked: 52
- Habener, 1993, The incretin notion and its relevance to diabetes. In: Vinik AI (ed) Gastrointestinal Hormones in Medicine., WB Saunders Company, Philadelphia, vol, 22, 775
- Zunz, 1929, Contributions a l’etude des variations physiologiques de la secretion interne du pancreas: realations entre les secretions externe et interne du pancreas., Arch Int Physiol Biochim, 31, 20
- Dixon, 1926, The action of intestinal extracts., Br Med J, 1, 820, 10.1136/bmj.1.3410.820 · doi:10.1136/bmj.1.3410.820
- Rabinovitch, 1972, Insulinotropic and glucagonotropic activities of crude preparation of cholecystokinin-pancreozymin., Clin Res, 20, 945
- Elahi, 1979, Pancreatic α- andβ -cell responses to GIP infusion in normal man, Am J Physiol, 237, E185
- Brown, 1976, GI hormones and insulin secretion. In: James VHT (ed) 5th International Congress on Endocrinology, Excerpta Medica, Hamburg, vol 2, 568
- Bunnett, 1986, Immunocytochemical localization of gastric inhibitory polypeptide and glucagon in the alimentary tract of ruminants., Q J Exp Physiol, 71, 433, 10.1113/expphysiol.1986.sp003002 · doi:10.1113/expphysiol.1986.sp003002
- Thomsen, 1972, The amino acid sequence of human glucagon., FEBS Lett, 21, 315, 10.1016/0014-5793(72)80192-3 · doi:10.1016/0014-5793(72)80192-3
- Sundby, 1974, Camel glucagon: isolation, crystallization and amino acid composition., Horm Metab Res, 6, 425, 10.1055/s-0028-1095723 · doi:10.1055/s-0028-1095723
- Sundby, 1972, Rabbit glucagon: isolation, crystallization and amino acid composition., Horm Metab Res, 4, 56, 10.1055/s-0028-1097080 · doi:10.1055/s-0028-1097080
- Bromer, 1971, Amino acid sequence of bovine glucagon., J Biol Chem, 246, 2822, 10.1016/S0021-9258(18)62256-2 · doi:10.1016/s0021-9258(18)62256-2
- Yu, 1989, Opossum insulin, glucagon and pancreatic polypeptide: amino acid sequences., Peptides, 10, 1195, 10.1016/0196-9781(89)90012-0 · doi:10.1016/0196-9781(89)90012-0
- Pollock, 1975, Isolation and amino acid sequence studies., J Biol Chem, 250, 9377, 10.1016/S0021-9258(19)40654-6 · doi:10.1016/s0021-9258(19)40654-6
- Markussen, 1972, Turkey glucagon: crystallization, amino acid composition and immunology., Horm Metab Res, 4, 360, 10.1055/s-0028-1094032 · doi:10.1055/s-0028-1094032
- Sundby, 1972, Crystallization and amino acid sequence of duck glucagon., FEBS Lett, 26, 289, 10.1016/0014-5793(72)80595-7 · doi:10.1016/0014-5793(72)80595-7
- Ferriera, 1991, Purification and primary structure of glucagon from ostrich pancreas splenic lobes., Int Pept Protein Res, 38, 90, 10.1111/j.1399-3011.1991.tb01415.x · doi:10.1111/j.1399-3011.1991.tb01415.x
- Conlon, 1990, Isolation and structural characterization of insulin, glucagon and somatostatin from the turtle, Psudemys scripta., Peptides, 11, 461, 10.1016/0196-9781(90)90043-5 · doi:10.1016/0196-9781(90)90043-5
- Cavanaugh, 1996, Isolation and structural characterization of proglucagon-derived peptides, pancreatic polypeptide, and somatostatin from the Urodele Amphiuma tridactylum., Gen Comp Endocrinol, 101, 12, 10.1006/gcen.1996.0003 · doi:10.1006/gcen.1996.0003
- Conlon, 1989, Multiple molecular forms of insulin and glucagon-like peptide from the Pacific ratfish (Hydrolagus colli)., Gen Comp Endocrinol, 73, 136, 10.1016/0016-6480(89)90064-6 · doi:10.1016/0016-6480(89)90064-6
- Berks, 1989, Isolation and structural characterization of insulin and glucagon from the holocephalan species Callorhynchus milii (elephantfish)., Biochem J, 263, 261, 10.1042/bj2630261 · doi:10.1042/bj2630261
- Conlon, 1993, Primary structures of glucagon and glucagon-like peptide isolated from the intestine of the parasitic phase lamprey Petromyzon marius., Gen Comp Endocrinol, 91, 96, 10.1006/gcen.1993.1109 · doi:10.1006/gcen.1993.1109
- Unger, 1961, Sites of origin of glucagon in dogs and humans., Clin Res, 9, 53
- Ravazzola, 1979, Glicentin immunoreactive cells: their relationship to glucagon-producing cells., Endocrinology, 105, 499, 10.1210/endo-105-2-499 · doi:10.1210/endo-105-2-499
- Orci, 1983, Glucagon and glicentin producing cells. In: Lefébre PJ (ed) Glucagon I., Springer, Berlin, vol, 66, 57
- Leduque, 1982, Ontogeny of immunoreactive glicentin in the human gastrointestinal tract and endocrine pancreas., Regul Pept, 4, 261, 10.1016/0167-0115(82)90119-7 · doi:10.1016/0167-0115(82)90119-7
- Saifia, 1998, Galanin inhibits glucagon-like peptide-1 secretion through pertussis toxin-sensitive G protein and ATP-dependent potassium channels in rat ileal L-cells., J Endocrinol, 157, 33, 10.1677/joe.0.1570033 · doi:10.1677/joe.0.1570033
- Philippe, 1995, Islet-specific proteins interact with the insulin-response element of the glucagon gene., J Biol Chem, 270, 3039, 10.1074/jbc.270.7.3039 · doi:10.1074/jbc.270.7.3039
- Rothenberg, 1996, Evidence of redundancy in propeptide/prohormone convertase activities in processing proglucagon: an antisense study., Mol Endocrinol, 10, 331
- Rindi, 1990, Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice., Am J Pathol, 136, 1349
- Wider, 1976, Elevated gut glucagon-like immunoreactive material in human and experimental diabetes and its suppression by somatostatin., Metabolism, 25, 1487, 10.1016/S0026-0495(76)80174-6 · doi:10.1016/s0026-0495(76)80174-6
- O’Connor, 1979, The use of perfused rat intestine to characterize the glucagon-like immunoreactivity released into serosal secretions following stimulation by glucose., Horm Metab Res, 11, 19, 10.1055/s-0028-1092674 · doi:10.1055/s-0028-1092674
- Wojcikowski, 1985, Release of glucagon-like immunoreactive material (GLI) from the isolated perfused jejunum of normal and diabetic rats., Horm Metab Res, 17, 105, 10.1055/s-2007-1013463 · doi:10.1055/s-2007-1013463
- Valverde, 1979, Chromatographic pattern of gut glucagon-like immunoreactivity (GLI) in plasma before and after glucose absorption., Horm Metab Res, 11, 343, 10.1055/s-0028-1092735 · doi:10.1055/s-0028-1092735
- Sasaki, 1993, GLP-1 secretion coupled with Na/glucose transporter from the isolated perfused canine ileum., Digestion, 54, 365
- Barber, 1991, Fatty acids stereospecifically stimulate neurotensin release and increase [Ca2+]i in enteric endocrine cells, Am J Physiol, 261, G497
- Matsuyama, 1975, Glucose, insulin, pancreatic glucagon-like immunoreactive materials in the plasma of normal and diabetic children: effect of the initial insulin treatment., Horm Metab Res, 7, 452, 10.1055/s-0028-1093702 · doi:10.1055/s-0028-1093702
- Barber, 1987, Somatostatin and muscarinic inhibition of canine enteric endocrine cells: cellular mechanisms, Am J Physiol, 253, G684
- Wolfe, 1999, Glucose-dependent insulinotropic polypeptide (GIP): incretin vs. enterogastrone. In: Greeley GH (ed) Gastrointestinal Endocrinology., Humana Press, Totowa, NJ, vol, 8, 439
- Greenberg, 1987, Influence of vagal integrity on gastrin and somatostatin release in dogs., Gastroenterology, 93, 994, 10.1016/0016-5085(87)90561-0 · doi:10.1016/0016-5085(87)90561-0
- Costa, 1982, Neuronal peptides in the intestine., Br Med Bull, 38, 247, 10.1093/oxfordjournals.bmb.a071768 · doi:10.1093/oxfordjournals.bmb.a071768
- Bruzzone, 1983, Effect of bombesin on plasma insulin, pancreatic glucagon, and gut glucagon in man., J Clin Endocrinol Metab, 56, 643, 10.1210/jcem-56-4-643 · doi:10.1210/jcem-56-4-643
- Sagor, 1985, Influence of somatostatin and bombesin on plasma enteroglucagon and cell proliferation after intestinal resection in the rat., Gut, 26, 89, 10.1136/gut.26.1.89 · doi:10.1136/gut.26.1.89
- Matsuyama, 1980, Decrease in blood glucose and release of gut glucagon-like immunoreactive materials by bombesin infusion in the dog., Endocrinol Jpn, 27, 115, 10.1507/endocrj1954.27.Supplement_115 · doi:10.1507/endocrj1954.27.supplement_115
- Herrmann, 1993, Regulation of glucagon-like peptide release from the isolated perfused rat ileum by nutrients, peptides and neuromediators., Digestion, 54, 367
- Layer, 1993, GLP-1: a humoral mediator of the ileal brake in humans?, Digestion, 54, 385
- D’Alessio, 1994, Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal., J Clin Invest, 93, 2263, 10.1172/JCI117225 · DOI · Paper page
- Toft-Nielsen, 1996, The effect of GLP-1 on glucose elimination., Diabetes, 45, 552
- Tsai, 1997, Biological determinants of intestinotrophic properties of glucagon-like peptide 1 in vivo, Am J Physiol, 272, G662
- Gros, 1992, Characterization of high affinity receptors for glucagon-like peptide (7-36)amide on a somatostatin-secreting cell line., Biomed Res, 13, 143
- Kanse, 1988, Identification and characterization of glucagon-like peptide-1-7-36 amide in rat brain and lung., FEBS Lett, 267, 78
- Tronier, 1985, Absence of incretin effect in obese type II and diminished effect in lean type II and obese subjects, Diabetes Res Clin Pract, S568
- Habener, 1997, Proglucagon gene structure and regulation of expression. In: Fehmann HC, Göke B (eds) The Insulinotropic Gut Hormone Glucagon-like Peptide-1., Karger, Basel, vol, 13, 15
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2005) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,545
Van den Berghe, G., Wouters, P. J., Bouillon, R., Weekers, F., Verwaest, C., Schetz, M., Vlasselaers, D., Ferdinande, P., & Lauwers, P. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000045568.12881.10 · Cited by 1,455
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions
Vaudry, D., Gonzalez, B. J., Basille, M., Yon, L., Fournier, A., & Vaudry, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01449-2 · Cited by 1,121
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Sherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
PKA-Dependent and PKA-Independent Pathways for cAMP-Regulated Exocytosis
Seino, S., & Shibasaki, T. (2005) · Physiological Reviews · doi:10.1152/physrev.00001.2005 · Cited by 563
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
“Endocrine tumors Pheochromocytomas 12/20 (60) 3,970 6 1,002 Paragangliomas 5/18 (28) 1,353 6 601 Medullary thyroid carcinomas 5/18 (28) 1,326 6 264 Adrenal cortical adenomas 0/7 (0) Parathyroid carcinomas 0/4 (0) Pituitary adenomas 0/38 (0) Tumors of nervous system Meningiomas 7/20 (35) 989 6 271 Astrocytomas 4/16 (25…”
BackgroundMethodInfluentialRole of neuropeptides in appetite regulation and obesity – A review
Arora, S., & Anubhuti (2006) · Neuropeptides · doi:10.1016/j.npep.2006.07.001 · Cited by 455
Serine peptidases: Classification, structure and function
Page, M. J., & Di Cera, E. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7565-9 · Cited by 438
Discovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Self-citationMinireview: The Glucagon-Like Peptides
Drucker, D. J. (2001) · Endocrinology · doi:10.1210/en.142.2.521 · Cited by 421
Yi, F., Brubaker, P. L., & Jin, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411487200 · Cited by 413
Intercellular signals regulating pancreas development and function
Kim, S. K., & Hebrok, M. (2001) · Genes & Development · doi:10.1101/gad.859401 · Cited by 402
Gribble, F. M., Williams, L., Simpson, A. K., & Reimann, F. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1147 · Cited by 393
Holz, G. G. (2004) · Diabetes · doi:10.2337/diabetes.53.1.5 · Cited by 391
Critical Role of cAMP-GEFII·Rim2 Complex in Incretin-potentiated Insulin Secretion
Kashima, Y., Miki, T., Shibasaki, T., Ozaki, N., Miyazaki, M., Yano, H., & Seino, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108378200 · Cited by 381
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 347
Gastrointestinal hormones regulating appetite
Chaudhri, O., Small, C., & Bloom, S. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 346
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Puddu, A., Sanguineti, R., Montecucco, F., & Viviani, G. L. (2014) · Mediators of Inflammation · doi:10.1155/2014/162021 · Cited by 342
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption
Henriksen, D. B., Alexandersen, P., Bjarnason, N. H., Vilsbøll, T., Hartmann, B., Henriksen, E. E., Byrjalsen, I., Krarup, T., Holst, J. J., & Christiansen, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2180 · Cited by 332
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Liu, Z., & Habener, J. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706105200 · Cited by 326
Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis
Lee, S., Xie, J., & Chen, X. (2010) · Chemical Reviews · doi:10.1021/cr900361p · Cited by 324
Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318
Insulin Signaling in α Cells Modulates Glucagon Secretion In Vivo
Kawamori, D., Kurpad, A. J., Hu, J., Liew, C. W., Shih, J. L., Ford, E. L., Herrera, P. L., Polonsky, K. S., McGuinness, O. P., & Kulkarni, R. N. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.007 · Cited by 316
Obesity and diabetes: An update
Verma, S., & Hussain, M. E. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.06.017 · Cited by 318
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Peptide-Based Probes for Targeted Molecular Imaging
Lee, S., Xie, J., & Chen, X. (2010) · Biochemistry · doi:10.1021/bi901135x · Cited by 310
Abraham, E. J. (2002) · Endocrinology · doi:10.1210/en.143.8.3152 · Cited by 310
Kang, G., Joseph, J. W., Chepurny, O. G., Monaco, M., Wheeler, M. B., Bos, J. L., Schwede, F., Genieser, H.-G., & Holz, G. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211682200 · Cited by 298
Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial
Lustig, R. H., Hinds, P. S., Ringwald-Smith, K., Christensen, R. K., Kaste, S. C., Schreiber, R. E., Rai, S. N., Lensing, S. Y., Wu, S., & Xiong, X. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030003 · Cited by 299
Zhao, T., Parikh, P., Bhashyam, S., Bolukoglu, H., Poornima, I., Shen, Y.-T., & Shannon, R. P. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.100982 · Cited by 297
Ahrén, B., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1030 · Cited by 292
Glucose-Sensing in Glucagon-Like Peptide-1-Secreting Cells
Reimann, F., & Gribble, F. M. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2757 · Cited by 292
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Dose-dependent satiating effect of whey relative to casein or soy
Veldhorst, M. A. B., Nieuwenhuizen, A. G., Hochstenbach-Waelen, A., van Vught, A. J. A. H., Westerterp, K. R., Engelen, M. P. K. J., Brummer, R.-J. M., Deutz, N. E. P., & Westerterp-Plantenga, M. S. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.01.004 · Cited by 270
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271
Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
Hsieh, F.-C., Lee, C.-L., Chai, C.-Y., Chen, W.-T., Lu, Y.-C., & Wu, C.-S. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-35 · Cited by 256
Proliferation of sorted human and rat beta cells
Parnaud, G., Bosco, D., Berney, T., Pattou, F., Kerr-Conte, J., Donath, M. Y., Bruun, C., Mandrup-Poulsen, T., Billestrup, N., & Halban, P. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0855-1 · Cited by 232
Small-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“GLP-1R is widely expressed in various tissues including pancreatic islets, pancreatic ducts, kidney, lung, heart, skin, immune cells, and the central and peripheral nervous systems, hypothalamus, hippocampus, and the cortex [58].”
BackgroundBrereton, M. F., Vergari, E., Zhang, Q., & Clark, A. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415583535 · Cited by 206
Insulin Sensitivity from Meal Tolerance Tests in Normal Subjects: A Minimal Model Index
Caumo, A., Bergman, R. N., & Cobelli, C. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6982 · Cited by 206
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
“metabolism by DPP-IV and, in addition, is rapidly cleared by renal elimination [18].”
RetractedLiu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179
Ueda, S.-Y., Yoshikawa, T., Katsura, Y., Usui, T., & Fujimoto, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0190 · Cited by 178
Recent advances in biosensor technology in assessment of early diabetes biomarkers
Salek-Maghsoudi, A., Vakhshiteh, F., Torabi, R., Hassani, S., Ganjali, M. R., Norouzi, P., Hosseini, M., & Abdollahi, M. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.07.047 · Cited by 174
Role of the glucagon-like-peptide-1 receptor in the control of energy balance
Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173
Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S. (2007) · Diabetes · doi:10.2337/db06-1182 · Cited by 158
Ojima, A., Ishibashi, Y., Matsui, T., Maeda, S., Nishino, Y., Takeuchi, M., Fukami, K., & Yamagishi, S.-I. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.09.016 · Cited by 156
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
“Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the two factors that account for most of the incretin effect [10].”
BackgroundIncretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
“Albiglutide (formerly known as albugon) is a long-acting GLP-1R agonist, developed by GlaxoSmithKline through the genetic fusion of two repeats of human GLP-1(7-36) molecules to recombinant human albumin.”
BackgroundInfluentialIs GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130
Pamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2002 · Cited by 126
“The insulinotropic effects of GIP and GLP-1 are transduced through specific G protein-coupled receptors on the -cell, resulting in stimulation of adenylyl cyclase (5, 46) and phospholipase A2 (9) and increased levels of intracellular Ca2 (20, 25).”
BackgroundActivation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Gaykema, R. P., Newmyer, B. A., Ottolini, M., Raje, V., Warthen, D. M., Lambeth, P. S., Niccum, M., Yao, T., Huang, Y., Schulman, I. G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci81335 · Cited by 123
Kemp, D. M., Ubeda, M., & Habener, J. F. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00064-3 · Cited by 122
Self-citationIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111
“It is well established that GLP-1 augments insulin secretion during intravenous glucose administration in healthy humans (1), and we have previously observed that GLP-1 infused for 30 min before and during an IVGTT increases the acute insulin response to glucose (18).”
BackgroundSalehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108
Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87
“Glucagon-like peptide-1 (GLP-1) is a glucose-dependent insulinotropic hormone produced by cleavage of pro-glucagon in intestinal L cells [1].”
BackgroundIncretin levels in polycystic ovary syndrome
Vrbikova, J., Hill, M., Bendlova, B., Grimmichova, T., Dvorakova, K., Vondra, K., & Pacini, G. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0097 · Cited by 81
Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72
Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12198 · Cited by 59
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Zhou, T., Zhang, M., Zhao, L., Li, A., & Qin, X. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00093.2016 · Cited by 54
Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
Metadata
- Authors
- Kieffer, T. J., & Francis Habener, J.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1999-12-01
- Volume
- 20
- Issue
- 6
- Pages
- 876-913
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2017518223
- Cited by
- 1,062
- References
- 542
- FWCI
- 21.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.